Our mission...
Our mission...
… is to develop novel concepts supported by scientific and technical solutions, that will provide efficient and effective substitute for time-consuming processes of drug development and testing, as a strong ground for personal health treatments.
MUSICO PLATFORM
The next generation muscle simulation – from genotype to phenotype
The next generation muscle simulation – from genotype to phenotype
Developed over 18 years and critically acclaimed in over 60 peer-reviewed journals, our MUSICO Platform consists of multiple submodules for simulating a wide variety of muscle experiments, from molecular kinetics affected by genetic mutations and protein-drug interactions to functional behavior of muscle cells and tissues up to whole organs.
With this set of industry-leading tools, we can help you expedite and reduce the cost and number of experiments for your muscle research and drug discovery or create better-personalized treatment strategies.
Latest News
Latest News
New NIH grant awarded
We are excited to announce FilamenTech’s participation in a new scientific project called “Analysis Tools for Fiber Diffraction of Muscle” (R01GM144555), supported by National Institute of General Medical Sciences of the National Institutes of Health. Principal investigator is Thomas C. Irving from Illinois Institute of...
02 January, 2023Collaboration with IIT and NASA
FilamenTech has recently started a collaboration with prof. Aleksandar G. Ostrogorsky from Illinois Institute of Technology, Chicago, IL, USA on performing simulations and data analysis for the optimization of the DiGS experiments conducted on Earth and at the ISS (International Space Station) within the project:...
02 January, 2023Successful completion of SilicoFCM EU project
Over the last 4 years, FilamenTech’s co-founders prof. Srboljub Mijailovich and Momcilo Prodanovic, along with FilamenTech’s scientific board members were involved in the project called “SilicoFCM – In Silico trials for drug tracing the effects of sarcomeric protein mutations leading to familial cardiomyopathy” (No 777204),...
31 December, 2022
Our expertise
Our expertise
Multiscale computational modeling
Designing and conducting experiments
Data Analysis
Guidance in drug development
Developing new strategies for effective treatment of myopathies
Research interests
Research interests
Research interests
Multiscale computational modeling of physical systems
Multiscale computational modeling of cardiac, skeletal and smooth muscles
In-silico drug testing
Genetic disease assessment and therapy
Neuromuscular disease assessment and therapy
X-ray diffraction in living cells
Thick/thin filament regulation by Calcium
Excitation-contraction couplling
Human cardiac mutations in database
Research partners
Peer-reviewed publications
Years of platform development
Case Studies
Case Studies
Predicting the effects of drugs that modulate calcium transients
Disopyramide Disopyramide, classified as a type I antiarrhythmic (i.e., a sodium channel blocker) is a potent negative inotrope. It has been used to decrease left ventricular outflow tract obstruction in obstructive HCM since first reports in the early 1980’s. Until recently it was not known...
04 January, 2023Multiscale modeling of left ventricle
Multiscale modeling of left ventricle In silico clinical trials are the future of medicine and virtual testing and simulation are the future of medical engineering. The use of a computational platform can reduce the costs and time required for developing new models of medical devices...
02 January, 2023Myosin mutations
Effect of Myosin Isoforms from Mouse to Human To understand how pathology-induced changes in contractile protein isoforms modulate cardiac muscle function, it is necessary to quantify the temporal-mechanical properties of contractions that occur under various conditions. Pathological responses are much easier to study in animal...
02 January, 2023
